ACM
CNTX icon

Aster Capital Management’s Context Therapeutics CNTX Stock Holding History

Aster Capital Management’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-52,792
Closed -$55.4K – 1312
2024
Q4 		$55.4K Hold
52,792
– – 0.02% 474
2024
Q3 		$103K Buy
+52,792
New +$117K 0.02% 372

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Aster Capital Management's CNTX Position: Q1 2025 in Review

Aster Capital Management sold out of Context Therapeutics (CNTX) in Q1 2025, closing a stake of 52,792 shares — an estimated $55.4K sold.

Aster Capital Management first reported a position in CNTX in Q3 2024 and held it in 2 quarters. The position peaked at $103K in Q3 2024. 42 funds tracked by Wall St. Rank hold CNTX as of Q1 2025.

  • Aster Capital Management reported no remaining Context Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Aster Capital Management sold 52,792 Context Therapeutics shares in Q1 2025, an estimated $55.4K.
  • Aster Capital Management first reported a position in Context Therapeutics in Q3 2024 and held it in 2 quarters.
  • Aster Capital Management's Context Therapeutics position peaked at $103K in Q3 2024.
  • 42 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2025.

Based on Aster Capital Management's 13F filing for Q1 2025, filed 15 May 2025.